Loading
A phase 2 trial of HLX22 and Trastuzumab deruxtecan in HER2-positive breast cancer, run by Shanghai Henlius Biotech, now recruiting.
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients is a phase 2 interventional study registered as NCT06832202 by Shanghai Henlius Biotech, with 50 participants planned, started 2025-04-16 and due to reach its primary completion in 2027-06-01. Interventions recorded: HLX22 and Trastuzumab Deruxtecan.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Shanghai Henlius Biotech, HER2-positive breast cancer and the tag pipeline.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/